AQP4 and Stroke: If one, for example, were to simply give an AQP4 blocker to stroke patients, timing would be critical; if given too early, it might reduce cytotoxic edema and tissue damage, but if continued too long, it could impair later edema clearance, worsening outcomes and becoming potentially fatal.